Журнал кардиореспираторных исследований 2025. №2/3

Тема статьи

PODAGRA KOMORBID KECHISHIDA BO’G’IM SINDROMI VA MARKAZIY GEMODINAMIKA BUZILISHINI O’RGANISH (30-35)

Авторы

Yarmuxamedova Saodat Xabibovna, Berdiyev Doniyor Hasan o’g’li

Учреждение

Samarqand Davlat Tibbiyot Universiteti

Аннотация

Podagra kasalligi nafaqat bo‘g‘im yallig‘lanish kasalliklari, balki yurak-qon tomir tizimida ham jiddiy muammolarni keltirib chiqaradi. Kasallikning o‘ziga xosligi giperurikemiya bilan bog‘liq bo‘lib, natriy urat kristallarining turli to‘qimalarga yig‘ilishi va bunda rivojlanuvchi yallig‘lanish jarayonlari bilan xarakterlanadi. Tadqiqotlar shuni ko‘rsatadiki, podagra bilan kasallangan bemorlarda yurak-qon tomir kasalliklari, xususan arterial gipertenziya, yurak ishemik kasalliklari, yurak yetishmovchiliklari va ateroskleroz kabi kasalliklar kelib chiqish xavfi yuqori. Ushbu xavf metabolik sindrom va immun tizimning disbalansi tufayli yanada ortadi. Podagra va yurak-qon tomir tizimi kasalliklari o‘rtasidagi ushbu kompleksning o‘zaro aloqalarini aniqlash va davolash usullarini takomillashtirish dolzarb ilmiy masala hisoblanadi.

Ключевые слова

podagra, transmetral oqim, chap qorincha arxitektonikasi, arterial gipertenziya, yurak ishemik kasalligi, komorbid.

Литературы

1. Tairov D.R., Berdiev D.KH. "Gout: Immunological and genetic characteristics of the disease." Volume: 3, Issue: 12, Dec- 2024. journals.academiczone.net. 2. Tairov D.R., Berdiev D.KH. "Characteristics of Cardiohemodynamic Disorders in Gout Disease." SCIENTIFIC PROGRESS. Volume 2, Issue 3, 2021. ISSN: 2181-1601. 3. Tairov D.R., Berdiev D.KH. "Medication and Non-Medication Methods to Eliminate Hyperuricemia in Gout." "Science and Education" Scientific Journal. Impact Factor 3.848. May 2023, Volume 4, Issue 5. 4. Tairov D.R., Berdiev D.KH. "Characteristics of Heart Functional Disorders in Gout Disease." GALAXY INTERNATIONAL INTERDISCIPLINARY RESEARCH JOURNAL (GIIRJ). ISSN (E): 2347-6915. Vol. 10, Issue 5, May 2022. 5. Tairov D.R., Berdiev D.KH. "Cardiovascular Damage and Metabolic Syndrome Comorbidities in Patients with Gout Disease." 2nd International Congress on Multidisciplinary Studies. Indonesia. February 20th, 2021. conferencepublication.com. 6. Nasonov E.L., Karateev D.E., Satibaldiyev A.M., et al. (2015). 7. Adams P.F. "Current Estimates from the National Health Interview Survey, 1996." Vital Health Stat. Vol. 10, 1999. 8. Saag K.G., Mikuls T.R. "Recent Advances in the Epidemiology of Gout." Curr. Rheumatol. Rep. Vol. 7, 2005, pp. 235–241. 9. Terkeltaub R.A. "Clinical Practice. Gout." N. Engl. J. Med. Vol. 349, 2003, pp. 1647–1655. 10. Tairov E.S., Tairov D.R. "Metabolic Syndrome in Gout: Its Relationship with Renal Functional Disorders." Questions of Science and Education. No. 28 (77), 2019. 11. Wallace K.L., Riedel A.A., Joseph-Ridge N. "Increasing Prevalence of Gout and Hyperuricemia Over 10 Years Among Older Adults in a Managed Care Population." J. Rheumatol. Vol. 31, 2004, pp. 1582–1587. 12. Tairov D.R., Makhmudova H.D. "Cardiovascular Damage in Patients with Gout." Scientific Progress. Vol. 2, No. 2, 2021, pp. 242–249. 13. Yarmukhamedova S.KH., Kamolova D.ZH. "Study of Myocardial Geometry in Hypertensive Patients Using Echocardiography." Achievements of Science and Education. No. 12 (53), 2019. 14. Eliseev M.S., Barskova V.G., Nasonov V.A. "Clinical Significance of Metabolic Syndrome in Gout." Clinical Gerontology. Vol. 12, No. 2, 2006, pp. 29–33. 15. Tairov E.S., Tairov D.R., Solovyev S.K. "Gout: Diagnosis and Treatment." Tashkent, Uzbekistan, 2020. 16. Sowers M.J., Whaley-Connell A., Hayden M.R. "The Role of Obesity in Cardiorenal Syndrome." Cardiorenal Medicine. Vol. 1, 2011, pp. 5–12. 17. Hayden M., Tyagi S.K. "Uric Acid: A New Perspective on an Old Cardiovascular Risk Marker." Nutr Metab (London). Vol. 1, 2004, p. 10. 18. Jalal D.I., Chonchol M., Chen W., Targher G. "Uric Acid as a Therapeutic Target in CKD." Am J. Dis., 2013, Vol. 61, pp. 134–146. 19. Johnson R.J., Segal M.S., Sautin Y., Nakagawa T., Feig D.I., Kang D.H., Gersch M.S., Benner S., Sanchez-Lozada L.G. "Potential Role of Sugar (Fructose) in the Epidemics of Hypertension, Obesity, and Metabolic Syndrome." Am J Clin Nutr. Vol. 86, 2007, pp. 899–906. 20. Steele T. "Human Urate Secretion: Pyrazinamide Suppression Test." Ann Intern Med. Vol. 79, 1973, pp. 734–737. 21. Suliman M.E., Johnson R.J., Garcia-Lopez E., et al. "J-Shaped Relationship Between Uric Acid and Mortality in CKD." Am J. Dis. Vol. 48, 2006, pp. 761–771. 22. Kan D.H., Nakagawa T., Feng L., Watanabe S., Han L., Mazzali M., Truong L., Harris R., Johnson R.J. "The Role of Uric Acid in Kidney Disease Progression." J Am Soc Nephrol. Vol. 13, 2002, pp. 2888–2897. 23. Tseng C. "Correlation of Urinary Albumin Excretion Rate with Uric Acid Levels in Type 2 Diabetes." Kidney Int. Vol. 68, 2005, pp. 796–801. 24. Ono I., Hosoya T., Gomi H., et al. "Serum Uric Acid and Kidney Failure Prognosis in IgA Nephropathy Patients." Nephron. Vol. 87, 2001, pp. 333–339. 25. Thomas G., Sehgal A.R., Kashyap S.R., Srinivas T.R., et al. "Metabolic Syndrome and Kidney Disease: A Systematic Review and Meta-Analysis." Clin J Am Soc Nephrol. Vol. 6, 2011, pp. 2364–2373. 26. Wright A.F., Rudan I., Hastie N.D., Campbell H. "The Complexity of Urate Transporters." Kidney Int. Vol. 78, 2010, pp. 446–452. 27. Gutman A.B., Yu T.F. "Urate Nephrolithiasis." Am J Med. Vol. 45, 1968, pp. 756–779.